About the Company

CTD Holdings (Other OTC: CTDH) is a clinical stage biotechnology company focused on the development of cyclodextrin-based therapies for the treatment of rare diseases and other indications. The Company’s lead product is Trappsol Cyclo, a hydroxypropyl-β-cyclodextrin (HPβCD) product for the treatment of Niemann-Pick Type C (NPC) disease. CTD Holdings has received Orphan Drug designation in the US and EU for Trappsol Cyclo, and plans to initiate a Phase I trial in the US and a Phase I/II trial in the EU in the first quarter of 2017. In addition to and development activities, the Company also sells cyclodextrins and related products for use in pharmaceutical, nutritional, and other products.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research